精准医学、糖尿病与美国食品药品监督管理局
美国食品药品监督管理局(FDA)长期致力于推动个性化医疗的更广泛应用,即通过整合患者基础状况的精确知识来更好地靶向FDA批准的疗法。尽管在肿瘤学和罕见遗传病领域取得了一些进展,但大多数标准普通内科适应症(包括1型和2型糖尿病)尚未实现精准导向疗法的益处。本文概述了在实现糖尿病治疗由患者遗传学和特定表型的精确知识指导的未来过程中,监管方面的期望和挑战。
要点
- FDA长期寻求通过整合患者精确知识来更广泛地应用个性化医疗。
- 精准医学在肿瘤学和罕见遗传病领域取得进展,但糖尿病等标准适应症尚未实现其益处。
- 科学进步必须在FDA将精准医学纳入糖尿病药物研发和审批监管之前发生。
核心结论
- 在FDA将精准医学纳入糖尿病药物研发和审批监管之前,1型和2型糖尿病两个疾病亚组的科学进步都必须发生。
研究设计与样本
- 本文为综述,提供监管期望和挑战的概述,未报告检索范围。
主要发现
- FDA长期寻求实现个性化医疗的更广泛应用,即通过整合患者基础状况的精确知识来更好地靶向FDA批准的疗法。
- 精准医学在肿瘤学和罕见遗传病领域取得了一些进展,但大多数标准普通内科适应症尚未实现精准导向疗法的益处,包括1型和2型糖尿病。
- 推动糖尿病预防和治疗迈向更精准未来的科学和监管考量在1型和2型糖尿病两个疾病亚组之间不同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The U.S. Food and Drug Administration (FDA) has long sought to achieve the broader use of personalized medicine, which is better targeting of FDA-approved therapies through incorporating precise knowledge of a patient's underlying condition to therapies optimally chosen to match those needs. While some strides have been made in precision medicine-particularly in oncology and rare genetic diseases-most of the standard general medicine indications have yet to realize the benefits of precision-guided therapies. This includes those for diabetes mellitus (DM), both type 1 and type 2. Although the scientific and regulatory considerations needed to move to a more "precise" future of DM prevention and treatment differ between the two disease subsets, scientific advances in both must occur before the FDA can incorporate precision medicine into its oversight of DM drug development and approval. This article provides an overview of the regulatory expectations and challenges in realizing a future where the therapeutics for DM are informed by precise knowledge of a patient's genetics and specific phenotype.
引用
- Meyer RJ. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration. Diabetes Care. 2016. PMID: 27926889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。